Works by Tetteh, Ernestina

Results: 4
    1

    Phase 1 trial of the oral AKT inhibitor MK-2206 plus carboplatin/paclitaxel, docetaxel, or erlotinib in patients with advanced solid tumors.

    Published in:
    Journal of Hematology & Oncology, 2014, v. 7, n. 1, p. 3, doi. 10.1186/1756-8722-7-1
    By:
    • Rhoda Molife, L.;
    • Li Yan;
    • Vitfell-Rasmussen, Joanna;
    • Zernhelt, Adriane M.;
    • Sullivan, Daniel M.;
    • Cassier, Philippe A.;
    • Eric Chen;
    • Biondo, Andrea;
    • Tetteh, Ernestina;
    • Siu, Lillian L.;
    • Patnaik, Amita;
    • Papadopoulos, Kyriakos P.;
    • De Bono, Johann S.;
    • Tolcher, Anthony W.;
    • Minton, Susan
    Publication type:
    Article
    2
    3

    A phase 1 study evaluating the combination of an allosteric AKT inhibitor (MK-2206) and trastuzumab in patients with HER2-positive solid tumors.

    Published in:
    Breast Cancer Research, 2013, v. 15, n. 6, p. 3, doi. 10.1186/bcr3577
    By:
    • Hudis, Clifford;
    • Swanton, Charles;
    • Janjigian, Yelena Y.;
    • Lee, Ray;
    • Sutherland, Stephanie;
    • Lehman, Robert;
    • Chandarlapaty, Sarat;
    • Hamilton, Nicola;
    • Gajria, Devika;
    • Knowles, James;
    • Shah, Jigna;
    • Shannon, Keith;
    • Tetteh, Ernestina;
    • Sullivan, Daniel M.;
    • Moreno, Carolina;
    • Yan, Li;
    • Han, Hyo Sook
    Publication type:
    Article
    4